I
t has been shown that inflammatory and immunological responses may play at least a partial role in the pathogenesis of atherosclerosis. [1] [2] [3] In the past, a number of antiinflammatory or immunosuppressive drugs were examined in in vivo animal experiments as to whether the drugs might have suppressive effects on the development and progression of atherosclerosis. 4, 5 However, the results were inconsistent among experiments in different laboratories, and the effect of immunodepression on atherogenesis remains inconclusive. 4 -6 Furthermore, most of these drugs induce nonspecific immunosuppression, thereby having serious side effects for longterm clinical use. 4, 5 Tranilast, N- (3,4-dimethoxycinnamoyl) anthranillic acid, has been used clinically as an oral antiallergic drug for nearly a decade in Japan. The antiallergic effects of tranilast are thought to be mediated by the inhibition of the release of chemical mediators from mast cells and basophils. 7 Very recently, a clinical trial showed that oral administration of tranilast for 3 months significantly prevented coronary restenosis with minimal side effects after directional coronary atherectomy in humans. 8 To the best of our knowledge, tranilast is the first anti-immunological drug to show inhibitory effects on atherosclerotic development without significant side effects during long-term use in vivo in humans. Mechanisms responsible for the inhibition of restenosis by tranilast remain undetermined. It has been shown that tranilast inhibits release of cytokines from activated human macrophages and T cells in vitro. 9 It is known that chronically activated macrophages and T cells within the lesion participate in local immune responses during atherogenesis and that various cytokines released from these cells affect growth, differentiation, and lipid metabolism in vascular cells and could thereby play a role in the development and progression of atherosclerosis. [1] [2] [3] Thus, we hypothesized that tranilast may suppress atherosclerosis, possibly through inhibitory effects on the functions of macrophages and T cells. We tested this hypothesis in Watanabe heritable hyperlipidemic (WHHL) rabbits and focused on the effects of tranilast treatment on the expression of the major histocompatibility complex (MHC) class II on macrophages and of interleukin-2 (IL-2) receptor on T cells in the atheromatous plaque and on isolated cells. MHC class II on macrophages and IL-2 receptor on T cells are known to contribute to the immunological responses and have been recognized as a marker of the local immunological activation in the atherosclerotic arterial walls. 2,10,11
Methods

Animal Experiments
Twenty-five WHHL rabbits (3 months old) weighing between 2.0 and 2.3 kg were housed individually in wire-bottomed cages in an air-conditioned room at 20°C and 50% humidity with 12 hours light/12 hours dark cycles. After an adaptation period of 1 week, the rabbits were randomly separated into 2 groups: 13 rabbits in the control group (standard chow containing placebo) and 12 rabbits in the tranilast-treated group (standard chow containing tranilast). Tranilast powder (Kissei Pharmaceutical Co) was mixed with the pelleted diet at an oral dose of 300 mg ⅐ kg body wt Ϫ1 ⅐ d Ϫ1 . This dose was selected because its oral administration maintained plasma concentrations of tranilast to Ϸ10 to 100 mol/L, which have an anti-immunological action in in vitro experiments. 12 Standard chows were purchased from Cler Japan Inc. The amount of daily diet for each animal was restricted to 120 g during the study period. Water was provided ad libitum.
At 6 months into the dietary period, arterial blood pressure and heart rate in conscious rabbits were measured by the central ear technique 13 in the early morning 2 hours after rabbits were provided access to the diet. Blood samples from the central ear artery after a 24-hour fast were collected into tubes containing EDTA-Na 2 (1 mg/mL blood) for the lipid assay. Then, rabbits were killed under pentobarbital anesthesia (30 mg/kg IV). The entire aortas from the aortic valve to the iliac bifurcation were excised and placed immediately into ice-cold PBS. The isolated aortas were cleaned of perivascular tissues. The aortas from the origin of the first intercostal arteries to the origin of the third intercostal arteries were used for assays of tissue lipids and for the immunohistological examination. The remaining aortas from the origin of the aortic valve to the first intercostal arteries and from the third intercostal arteries to the iliac bifurcation were used for morphometric assessment of atheromatous plaque area. 13 All experiments were performed in accordance with the guidelines on experimental animals issued by Kumamoto University School of Medicine and were approved by the Center for Laboratory Animals.
Atheromatous Plaque Area
The aortas from the origin of the aortic valve to the first intercostal arteries and from the third intercostal arteries to the iliac bifurcations were opened longitudinally to expose the intimal surface and were fixed in 10% buffered formalin overnight. The preparations were then stained with Sudan IV to reveal sudanophilic plaques and subsequently photographed. Then, the photographs were copied onto graph paper at ϫ2 magnification, and the outlines of the aorta and the Sudan-positive area were scanned and estimated by computerized planimetry, as reported previously. 13 The atheromatous plaque areas within each aorta were summed, and the extent of atheromatous plaques was expressed as a percentage of surface area of the aorta.
Lipid Analysis of EDTA Plasma and Aortic Samples
Parts of the aortas from the first to the third intercostal arteries were blotted, kept in an incubator for 48 hours at 60°C, and weighed. Measurements of lipids and lipoproteins in plasma and aortic tissues were performed with commercial kits (Wako Pure Chemical) as previously described. 13 
LDL Isolation and Oxidation
At 6 months into the dietary period, LDL (dϭ1.021 to 1.063) was isolated from both groups of WHHL rabbits by sequential ultracentrifugation. The oxidative susceptibility of LDL isolated from each rabbit was determined by measurement of diene formation as described previously. 14 
Immunohistochemistry
Parts of the aortas at the level between the first and the third intercostal arteries were rinsed and embedded in O.C.T. compound (Miles Inc), quickly frozen, and stored at Ϫ80°C. Frozen tissue specimens were cut into 8-m-thick sections and stained either by a single indirect immunoperoxidase method or by a sequential doublelabeling method 15 using the primary monoclonal antibodies listed in Table 1 .
Adjacent tissue sections from atherosclerotic lesions were examined to determine lesion size and cellularity in the atherosclerotic lesions. The area density was calculated by use of the cross-sectional area of the lesion measured by computerized image analysis. 
Immunofluorescence Staining and Fluorescence-Activated Cell Sorter Analysis
Antibodies used for flow cytometry were also listed in Table 1 . Peripheral blood mononuclear cells (PBMCs) were purified from citrate-anticoagulated venous blood samples from healthy volunteers by use of Ficoll-Hypaque gradients. 16 The isolated PBMCs (10 6 cells/mL) were incubated with or without recombinant human IL-2 (200 U/mL; Genzyme) in the presence or absence of tranilast at the indicated concentrations (3 to 300 mol/L) at 37°C for 24 hours in 5% CO 2 and 98% humidity. The concentrations, ranging from 3 to 300 mol/L tranilast, used in this in vitro experiment are comparable to the plasma levels in rabbits that had oral doses of 300 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 of tranilast (plasma concentration reached 450 mol/L 30 minutes after a single administration of 300 mg/kg of tranilast and decreased to 3 mol/L 24 hours after the single administration). After the incubation, expression of IL-2 receptor (CD25) on T cells (CD3-positive) was evaluated by flow cytometry with the direct method as described previously. 16, 17 CD25 (IL-2 receptor) expression on the treated T cells was expressed as the mean channel of fluorescence intensity among the CD3-positive cells (all T cells).
In the other set of experiments, human PBMCs (10 6 cells/mL) and rabbit monocytes isolated from peripheral blood were incubated with or without recombinant human interferon-␥ (IFN-␥; 100 ng/mL; Pharmingen) in the presence or absence of tranilast 3 to 300 mol/L at 37°C for 24 hours. Then, HLA-DP, DQ, DR (MHC class II) expression on human monocytes and class II RLA-DQ (MHC class II) expression on rabbit monocytes were also evaluated by flow cytometry with the direct and indirect methods, 18 respectively.
Measurements of Cytosolic Free Calcium in Monocytes
The concentration of cytosolic free calcium ([Ca 2ϩ ] i ) in the isolated monocytes was measured by use of the intracellular calcium indicator fura 2, as described previously. 16 [Ca 2ϩ ] i in single fura 2-loaded monocytes was monitored continuously with dual-excitation microfluorimetry equipment (ARGUS 50/CA System) coupled to an image acquisition system (Nikon inverted microscope). Monocytes adhering to plastic culture dishes were stimulated by For-Met-LeuPhe (FMLP; 100 nmol/L; Peptide Institute) in the presence or absence of tranilast 30 to 300 mol/L under continuous monitoring of [Ca 2ϩ ] i at 37°C. More than 95% of the adherent cells were CD14-positive cells.
Reagents
All reagents for cell culture were from Gibco. Other chemicals were from Sigma Chemical Co.
Statistical Analysis
All values were expressed as meanϮSEM. Statistical analysis of the data was performed with Student's t test for paired or unpaired observations. When Ͼ2 groups were compared, ANOVA was used. Values were considered to be statistically different at PϽ0.05.
Results
Body Weight and Hemodynamics
There was no significant difference in body weight (Control, 3.0Ϯ0.2 kg versus Tranilast, 3.2Ϯ0.2 kg, PϭNS), mean blood pressure (Control, 99Ϯ6 mm Hg versus Tranilast, 98Ϯ4 mm Hg, PϭNS), or heart rate (Control, 232Ϯ14 bpm versus Tranilast, 224Ϯ18 bpm, PϭNS) at 6 months (on the day of death) of the dietary period between the 2 groups of rabbits.
Aortic Plaque Area
The area of sudanophilic atheromatous plaque was significantly smaller in the tranilast-treated group than in the control group, as shown in Figure 1 .
Lipids in Plasma and in Aortic Tissues
There was no significant difference in the plasma levels of total cholesterol (Control, 472Ϯ50 mg/dL versus Tranilast, 548Ϯ31 mg/dL, PϭNS), triglycerides (Control, 398Ϯ45 mg/dL versus Tranilast, 444Ϯ54 mg/dL, PϭNS), or HDL cholesterol (Control,13Ϯ2 mg/dL versus Tranilast, 11Ϯ1 mg/dL, PϭNS) at 6 months (on the day of death) of the dietary period between the 2 groups. However, tissue concentrations of both total cholesterol and cholesteryl esters in the aortas were significantly lower in the tranilast-treated group than in the control group (total cholesterol, 25Ϯ4 versus 62Ϯ12 g/mg protein, respectively, PϽ0.01; cholesteryl esters, 19Ϯ3 versus 48Ϯ9 g/mg protein, respectively, PϽ0.01).
Oxidative Susceptibility of LDL
Susceptibility of isolated rabbit LDL (300 g protein/mL) to oxidative modification with Cu 2ϩ 5 mol/L was not different between the control and tranilast-treated groups (lag time of diene formation: Control, 63Ϯ3 minutes versus Tranilast, 61Ϯ2 minutes, nϭ6 in each experiment, PϭNS). Also, the addition of tranilast to the incubation mixture containing LDL isolated from the control rabbits did not affect the lag time of conjugated diene formation (diene lag time: 61Ϯ2 minutes without tranilast versus 60Ϯ3 minutes with tranilast 300 mol/L, nϭ6 in each experiment, PϭNS).
Histological Findings
There was no significant difference in the percentage of RAM11-positive macrophage area in the intimal plaque area between the placebo-and tranilast-treated groups, as shown in Table 2 . Most of the MHC class II antigen-positive cells were identical with macrophages ( Figure 2 ), a result in agreement with previous reports. 4, 10 Table 2 shows that the ratio of class II MHC antigen-positive cells to RAM11-positive macrophages was significantly lower in the tranilasttreated group than in the control group.
As shown in Figure 3A , most T cells (CD5-positive) were localized in the subendothelium. CD25-positive cells (IL-2 receptor-positive cells) were found to be identical with T cells ( Figure 3B ). As shown in Table 3 , there was no difference in the number of T cells (CD5-positive) in the intimal plaque area between the 2 rabbit groups. The percentage of CD25-positive cells (IL-2 receptor-positive cells) in all T cells (CD5-positive) was significantly lower in the tranilast-treated group than in the control group (Table 3) . 
Effect of Tranilast on Cell Surface Antigen Expression on Isolated PBMCs
Effect of Tranilast on FMLP-Induced Transients of [Ca 2؉ ] i in Monocytes
Discussion
The present study showed that tranilast, an antiallergic drug, suppressed atheromatous formation and decreased contents of cholesterol and cholesteryl esters in the aortas of WHHL rabbits. These inhibitory effects of tranilast were associated with the suppression of MHC class II expression on monocytes/macrophages and of IL-2 receptor (CD25) expression on T cells, both of which are known to contribute to the immunological responses and have been recognized as a marker of the local immunological activation in the atherosclerotic arterial walls. 2, 10, 11 Tranilast is unlikely to exert [1] [2] [3] 19 The activated macrophages, in turn, can secrete a variety of potentially atherogenic mediators, including monocyte/macrophage-derived growth factors, lipoprotein lipase, cytotoxic substances, plasminogen activators, and substances that regulate LDL metabolism. [1] [2] [3] 10 Thus, the present study suggests that tranilast may suppress the activation of T cells and macrophages in atherosclerotic plaques, possibly leading to the inhibition of production/secretion of cytokines promoting atherosclerosis from these cells. This may explain the suppressive effects of tranilast on the atheromatous formation in WHHL rabbits.
It has been shown that IFN-␥ secreted from the activated T cells in turn stimulates MHC class II expression in macrophages, 18, 20 and IL-2 from the T cells stimulates IL-2 receptor expression in T cells themselves in an autocrine manner. 2, 3, 20 In this context, the present study further showed that tranilast suppressed both IFN-␥-induced expression of MHC class II in the isolated macrophages and IL-2-induced expression of IL-2 receptor in the isolated T cells in in vitro experiments, using concentrations of tranilast comparable to the plasma level in WHHL rabbits that were treated with the oral dose of 300 mg ⅐ kg body wt Ϫ1 ⅐ d Ϫ1 used in the present study. These results indicate that the inhibitory effects of tranilast on the actions of IFN-␥ and IL-2 may contribute to the lower frequencies of macrophages with MHC class II antigen and of T cells with IL-2 receptor in atheromatous plaque in WHHL rabbits treated with tranilast. MHC class II antigen is reported to appear in some smooth muscle cells in the atheromatous plaques, 21 and IL-2 receptor is also expressed in certain macrophages and B cells. 11 However, MHC class II antigen in smooth muscle cells and IL-2 receptor in macrophages were rarely shown in the intimal plaque area in the present study.
Various mechanisms of these suppressions with tranilast can be considered. A variety of cellular responses need elevation of [Ca 2ϩ ] i in the isolated macrophage, and a rise in [Ca 2ϩ ] i has been implicated to have a regulatory role in various functions in macrophages. 22 Considering that tranilast suppressed the elevation of [Ca 2ϩ ] i in response to FMLP in macrophages, as shown in the present study, tranilast may suppress MHC class II expression in macrophages partially through the mechanism mediated by inhibition of intracellular calcium mobilization.
Most RAM11-positive macrophages and CD5-positive T cells in the atherosclerotic intima are derived from circulating monocytes and T cells. The recruitment of these cells has been shown to involve redox-sensitive mechanisms. 23 In this sense, lack of antioxidant effect in tranilast may possibly cause failure to inhibit the recruitment of these cells into the arterial intima on the basis of the present finding of comparable numbers of these cells in the plaques between tranilastand placebo-treated rabbits. Thus, tranilast is unlikely to exert nonspecific inhibition of all functions of macrophages and T cells, but it might inhibit their interactions and the subsequent activation of these cells only after their recruitment into the arterial intima. From this point of view, the present study strongly suggests that immune activation of monocytes/macrophages and T cells after their recruitment into the arterial intima may play an important role in foam cell formation.
In conclusion, tranilast merits further investigation as an agent that may be therapeutically useful for suppression of atherosclerotic development.
